Skip to main content

Table 1 Characteristics of patients according to treatment group (matched cohort)

From: The watch-and-wait strategy versus surgical resection for rectal cancer patients with a clinical complete response after neoadjuvant chemoradiotherapy

  Surgical group (N = 94) Watch-and-wait group (N = 94) P
Age-median (IQR), year 56.0 (49.0–62.3) 57.5 (46.0–65.0) 0.760b
Sex    
 Male 51 (54.3%) 55 (58.5%) 0.556a
 Female 43 (45.7%) 39 (41.5%)  
WHO performance status-N (%)    0.665a
 0 54 (57.4%) 49 (52.1%)  
 1 39 (41.5%) 43 (45.7%)  
 2 1 (1.1%) 2 (2.1%)  
T stage-N (%)    0.883a
 T2 8 (8.5%) 9 (9.6%)  
 T3 71 (75.5%) 68 (72.3%)  
 T4 15 (16.0%) 17 (18.1%)  
N stage-N (%)    0.385a
 N0 24 (25.5%) 19 (20.2%)  
 N1/2 70 (74.5%) 75 (79.8%)  
Distance from anal verge-median (IQR), cm 4.0 (3.0–5.0) 4.0 (3.0–5.0) 0.996b
CEA-median (IQR), ng/ml 2.86 (1.71–4.77) 2.82 (1.61–4.74) 0.770b
Radiation dose, median (IQR), Gy 50 (50–50) 50 (50–50) 0.686b
Chemotherapy regimen-N (%)    0.875a
 Capecitabine or fluorouracil only 29 (30.9%) 30 (31.9%)  
 Capecitabine or fluorouracil plus oxaliplatin 65 (69.1%) 64 (68.1%)  
Therapeutic patterns in the neoadjuvant setting-N (%)
 Concurrent chemoradiotherapy only 21 (22.3%) 26 (27.7%) 0.501a
 Concurrent chemoradiotherapy plus induction and/or consolidation chemotherapy 73 (77.7%) 68 (72.3%)  
  1. Data are showed in N (%) or median (interquartile range [IQR])
  2. aP values were determined by χ2 test
  3. bP values were determined by Mann–Whitney U test